Prioritizing long-acting injectable antiretroviral therapy among key populations: Perceptions of persons living with HIV who inject drugs, ART clinic staff, and policymakers in Vietnam [0.03%]
越南HIV阳性注射吸毒者、抗逆转录病毒治疗门诊工作人员和政策制定者对长效注射型抗逆转录病毒疗法的优先使用看法调查
Minh X Nguyen,Vivian F Go,Adams L Sibley et al.
Minh X Nguyen et al.
Objectives: We explored perceptions of long-acting injectable (LAI) patient prioritization and decision-making among people who inject drugs (PWID) with HIV, HIV clinic staff, and policymakers in Vietnam. ...
Jennifer Manne-Goehler,Nomathemba Chandiwana
Jennifer Manne-Goehler
Marco Vitoria,Graeme Meintjes,Nathan Ford et al.
Marco Vitoria et al.
Laura Waters,Nicola Mackie
Laura Waters
Accelerating Uptake of Optimal Antiretrovirals for Children and Adolescents Living With HIV in Nigeria, Tanzania, Uganda and Zambia Through Data-driven Quality Improvement Interventions [0.03%]
通过数据驱动的质量改进干预措施加速尼日利亚、坦桑尼亚、乌干达和赞比亚HIV感染儿童和青少年最佳抗逆转录病毒疗法的采用
Stephanie Dowling,Stephanie Hackett,Lauren Simao et al.
Stephanie Dowling et al.
Background: Limited access to disaggregated pediatric antiretroviral therapy (ART) data by weight, as recommended by the World Health Organization, made treatment optimization challenging. This article describes the treat...
In vitro evidence that Antiretroviral Therapy (ART) enhances protection against dental erosion in People Living with HIV (PLHIV) and individuals on Pre-Exposure Prophylaxis (PrEP) [0.03%]
抗逆转录病毒疗法(ART)可增强艾滋病毒感染者和暴露前预防用药个体口腔抗酸磨损的证据
Nayara Flores Macedo,Tommy Baumann,Marília Afonso Rabelo Buzalaf et al.
Nayara Flores Macedo et al.
Objective: This study aimed to evaluate the protective capacity of the salivary pellicle in people living with HIV (PLHIV) on antiretroviral therapy (ART) and individuals on pre-exposure prophylaxis (PrEP) for HIV. ...
BREATHER plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to [0.03%]
BREATHER plus临床试验设计：一项随机非劣效性研究，评估短期周期（5天用药，2天停药）多替拉韦/富马酸替诺福韦酯为基础的三联抗逆转录病毒疗法与每日一次抗逆转录病毒药物在12至20岁且病毒学抑制的青少年艾滋病患者中的疗效、安全性和可接受性
Fredrick Katongole,Tiyara Arumugam,Angus Jennings et al.
Fredrick Katongole et al.
Background: Novel strategies to improve ART adherence, retention in care and quality of life among adolescents living with HIV (ALHIV) are needed. Short-Cycle Therapy (SCT) with 4/5 sequential days on ART, 2/3 days off AR...
Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study [0.03%]
马拉维一项混合方法研究：多拉韦林抗逆转录病毒疗法背景下9岁或以下儿童实现病毒学抑制的障碍因素
Khumbo Phiri,Christine Hagstrom,Eric Lungu et al.
Khumbo Phiri et al.
After the transition to pediatric dolutegravir-based regimens, viral load (VL) suppression among children with HIV (CWH) in Malawi has remained suboptimal. This mixed-methods study assessed factors associated with high VL among young CWH on...
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis [0.03%]
初治HIV-1感染者接受B/F/TAF与其它抗逆转录病毒疗法的系统综述和网状meta分析：安全性比较
Tristan Curteis,Lucy A Eddowes,Megan Chen et al.
Tristan Curteis et al.
Aim: Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a single-tablet regimen approved for the treatment of HIV-1 in treatment-naive (TN) and virologically suppressed people with HIV-1 (PWH). While the efficacy of antiretro...
Kudakwashe Musomekwa,Brian van Wyk
Kudakwashe Musomekwa
The national prevalence of HIV among adults in Zimbabwe was 10.4% in 2023, while the HIV prevalence in Bulawayo Metropolitan Province was 11.7%. The country achieved the UNAIDS Fast Track goals of 95-95-95 ahead of the 2030 target, by repor...
耗时 0.31886 秒，为您在
48229835
条记录里面共找到 3757 篇文章 [XML]